Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

Cancer

Volumn 106, Issue 9, 2006, Pages 1933-1939

  Chi, Dennis S ^a   McCaughty, Kristina ^a   Diaz, John P ^b   Huh, Jae ^a   Schwabenbauer, Sarah ^a   Hummer, Amanda J ^a   Venkatraman, Ennapadam S ^a   Aghajanian, Carol ^a   Sonoda, Yukio ^a   Abu Rustum, Nadeem R ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Ovarian cancer; Recurrent ovarian cancer; Secondary cytoreduction; Surgery

Indexed keywords

PLATINUM;

ADULT; AGED; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNIVARIATE ANALYSIS;

ADULT; AGED; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PRACTICE GUIDELINES; PROGNOSIS;

EID: 33646364582     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21845     Document Type: Review

References (24)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
4. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M, editors. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott-Raven Publishers, 2005:895-987.
5. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273-280.
6. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
8. Cox DR. Regression models and life tables. R Stat Soc B. 1972;34:187-220.
9. Mazumdar, M, Classman J. Categorizing a prognostic variable: review of methods, codes for easy implementation and application to decision-making about cancer treatments. Stat Med. 2000;19:113-132.
10. Bowman AW, Azzalini A. Applied Smoothing Techniques for Data Analysis: The Kernel Approach with S-Plus illustrations. Oxford: Oxford University Press, 1997.
11. Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983;61:189-193.
12. Morris M, Gershenson DM, Wharton JT, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 1989;34:334-338.
13. Munkarah AR, Levenback C, Wolf JK, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 2001;81:237-241.
14. Janicke F, Holscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 1992;70:2129-2136.
15. Segna RA, Dottino Pr, Mandeli JP, et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993;57:61-65.
16. Vaccarello L, Rubin SC, Vlamis VGW, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol. 1995;57:61-65.
17. Lichtennegger W, Sehouli J, Buchmann E, et al. Operative results after primary and secondary debulking operations in advanced ovarian cancer (AOC). J Obstet Gynecol. 1998;24:447-451.
18. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144-153.
19. Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol. 2000;79:344-349.
20. Scarabelli C, Gallo A, Garbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504-512.
21. Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma. Obstet Gynecol. 2002;99:1008-1013.
22. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-1161.
23. Gronlund B, Lundvall L, Christensen IJ, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol. 2005;31:67-73.
24. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patient selection. Br J Cancer. 2005;92:1026-1032.